Difficulties in supplying the Zypadhera antipsychotic drugs have worsened to the point that the date of its delivery is now “Indeterminated”announced, Wednesday, August 13, the drug safety agency (ANSM). Zypadhera, an olanzapine -based treatment given in injection form to schizophrenic adult patients, has experienced supply problems in Europe since May 2024.
The ANSM says in a statement to have been “Informed by the CHEPLAPHARM Laboratory of delays in supplies in ZYPADHERA, linked to additional manufacturing and supply chain difficulties on its production site”. Furthermore, “Two lots could not be marketed due to a defect of quality”adds the health agency. Tensions mainly concern 300 mg and 405 mg dosages.
The laboratory, which was planned in July to make the drug available from September 2025, said that the date of resumption of supplies remained for the time being “Indeterminated”underlines the ANSM.
Move to the oral form of Olanzapine
The agency asks doctors to no longer start new treatments with Zypadhera so that patients already under treatment can continue to benefit from it. The ANSM also asks them to consider switching to the oral form of Olanzapine for patients in whom this is possible or to consider another antipsychotic if an injectable form with prolonged action is necessary.
The oral form of the drug supposes to take it more often. The risk is that the patient, often mentally unstable, no longer follow his treatment assiduously.
Zypadhera 300 mg imported has been made available since June 2025 in a transient and exceptional manner to meet the needs of patients in France, according to ANSM.
The difficulties of supplying psychotropic drugs persist in France, in particular for the quétapine, a neuroleptic often prescribed to treat schizophrenia, bipolarity and certain depressions.
